Skip to content

Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts

Randomized Trial of Rectal Indomethacin to Prevent Acute Pancreatitis in Patients Undergoing Endoscopic Ultrasound-guided Fine Needle Aspiration of Pancreatic Cysts

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05572788
Enrollment
600
Registered
2022-10-10
Start date
2022-09-26
Completion date
2025-12-31
Last updated
2024-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cyst, Pancreatitis, Acute

Brief summary

The aim of this randomized trial is to compare the rate of post-procedure pancreatitis in patients undergoing EUS-FNA of pancreatic cysts; patients will receive either a single dose of indomethacin or placebo administered rectally, during EUS-FNA.

Detailed description

Pancreatic cysts are pre-malignant lesions and are being increasingly diagnosed on cross-sectional imaging. Endoscopic ultrasound (EUS) is performed to further evaluate pancreatic cysts, and fine needle aspiration (FNA) is conducted to obtain a sample of the cystic fluid for analysis and examination for malignant cells. Acute pancreatitis is a complication of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of pancreatic cysts, which can lead to significant morbidity and substantial health care costs. The aim of this randomized trial is to compare the rate of post-procedure pancreatitis in patients undergoing EUS-FNA of pancreatic cysts; patients will receive either a single dose of indomethacin or placebo administered rectally, during EUS-FNA.

Interventions

PROCEDUREEUS-guided fine needle aspiration of pancreatic cysts

Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial

Sponsors

Orlando Health, Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Suspected or confirmed pancreatic cyst seen on imaging, requiring EUS-FNA

Exclusion criteria

* Unable to obtain consent from the participant or the participant's legally authorized representative (LAR) * Intrauterine pregnancy * Hypersensitivity reaction to Aspirin or NSAIDs * Patients with known history of chronic pancreatitis * Patients with known renal failure

Design outcomes

Primary

MeasureTime frameDescription
Rate of post-procedure pancreatitis following EUS-guided fine needle aspiration of pancreatic cysts30 daysPost-procedure pancreatitis is defined as the development of new or increased abdominal pain consistent with acute pancreatitis, and elevated amylase or lipase at least three times the upper limit of normal .

Secondary

MeasureTime frameDescription
Rate of procedure-related adverse events30 daysRate of adverse events resulting from EUS-FNA
Disease-related adverse events30 daysAny adverse event occurring as a result of underlying pancreatic cyst
Rate of mild, moderate and severe pancreatitis post-FNA30 daysRate of mild, moderate and severe pancreatitis post-FNA
Length of hospitalization in any patient hospitalized with any adverse event30 daysLength of hospitalization in any patient hospitalized with any adverse event
Length of hospitalization in any patient hospitalized with acute pancreatitis30 daysLength of hospitalization in any patient hospitalized with acute pancreatitis

Countries

United States

Contacts

Primary ContactBarbara J Broome
barbara.broome@orlandohealth.com321-841-7031

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026